KRAS and neoplasm: Second, considering the genetic heterogeneity of colorectal cancers[28,29], the absence of detectable KRAS mutations in the primary tumor may not formally exclude the presence of a KRAS mutation in metastases, and consequently, additional tumor samples need to be examined in order for KRAS mutations to correctly predict the KRAS status in metastatic lesions.